Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
357,75 €
-1,38 %
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Evercore ISI. They now have a $530.00 price target on the stock, up previously from $475.00.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Scotiabank.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $541.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $580.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Oppenheimer Holdings, Inc. from $540.00 to $600.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by HC Wainwright from $591.00 to $641.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Citigroup Inc. from $575.00 to $585.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Bank of America Corporation from $571.00 to $598.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Morgan Stanley from $570.00 to $596.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Truist Financial Corporation from $490.00 to $525.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) was upgraded by Maxim Group from "hold" to "buy". They now have a $575.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) was given a new $612.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its "overweight" rating reaffirmed by Morgan Stanley. They now have a $616.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
UBS_Group_AG in Discuss Fedex Corp.